Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Annika Grant"'
Publikováno v:
International Journal of Dermatology. 50:915-920
Human T-lymphotropic virus type 1 (HTLV-1) is a type C retrovirus primarily endemic to Japan, Central and South America, the Middle East, regions of Africa, and the Caribbean. Currently, an estimated 10-20 million people worldwide are infected with t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d7e4889b989776cc19528af46e92cff4
https://doi.org/10.1111/j.1365-4632.2011.04882.x
https://doi.org/10.1111/j.1365-4632.2011.04882.x
Publikováno v:
International Journal of Dermatology. 50:478-482
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::202e52af9c71235971190045718cd633
https://doi.org/10.1111/j.1365-4632.2010.04766.x
https://doi.org/10.1111/j.1365-4632.2010.04766.x
Publikováno v:
International Journal of Dermatology. 49:950-955
Summary Objective To evaluate the safety and efficacy of adalimumab for the management of hidradenitis suppurativa (HS). Methods In a prospective open-label phase II study, adalimumab was administered subcutaneously in a dose of 160 mg induction regi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b06ca3c9a63f92308db3ef66a5e2fd3d
https://doi.org/10.1111/j.1365-4632.2010.04545.x
https://doi.org/10.1111/j.1365-4632.2010.04545.x
Open label study to evaluate the efficacy of re-treatment with etanercept in patients with psoriasis
Autor:
Adriana, Abuchar, Magalys, Vitiello, Carlos, Ricotti, Annika, Grant, Luis, Dehesa, Francisco, Kerdel
Publikováno v:
Journal of drugs in dermatology : JDD. 11(8)
Etanercept has been used to treat chronic plaque psoriasis. Previously reported data demonstrated that some patients experienced secondary failure and frequently rotational-switch therapy is used. The re-treatment with etanercept as part of the rotat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f28b4bed971c277e2dabe619cb93757e
https://pubmed.ncbi.nlm.nih.gov/22859240
https://pubmed.ncbi.nlm.nih.gov/22859240
Publikováno v:
International journal of dermatology. 50(8)
Human T-lymphotropic virus type 1 (HTLV-1) is a type C retrovirus primarily endemic to Japan, Central and South America, the Middle East, regions of Africa, and the Caribbean. Currently, an estimated 10-20 million people worldwide are infected with t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::15e570871dac356573a86ad947b8315e
https://pubmed.ncbi.nlm.nih.gov/21781059
https://pubmed.ncbi.nlm.nih.gov/21781059
Publikováno v:
International journal of dermatology. 50(4)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2caa6229b31c709b9f86d3da6ae71432
https://pubmed.ncbi.nlm.nih.gov/21413963
https://pubmed.ncbi.nlm.nih.gov/21413963
Publikováno v:
International journal of dermatology. 49(8)
To evaluate the safety and efficacy of adalimumab for the management of hidradenitis suppurativa (HS).In a prospective open-label phase II study, adalimumab was administered subcutaneously in a dose of 160 mg induction regimen at week 0, followed by
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::d66379535d628e7d5b201aed9d76490c
https://pubmed.ncbi.nlm.nih.gov/23414167
https://pubmed.ncbi.nlm.nih.gov/23414167
Publikováno v:
Journal of the American Academy of Dermatology. 62(2)
Background Biologic therapies with anti–tumor necrosis factor agents are promising treatments for hidradenitis suppurativa (HS). Objective We assessed the efficacy and safety of infliximab (IFX) for the treatment of moderate to severe HS. Methods A
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d542deda23f13bdb8ec2edfaf64d46ca
https://pubmed.ncbi.nlm.nih.gov/21414503
https://pubmed.ncbi.nlm.nih.gov/21414503